Drug intelligence / Profile preview

[Dpr3]ghrelin(1-20)

Development stage
Unknown
Modality
Peptides
Administration
Intravenous, Subcutaneous, Intranasal, Intracerebroventricular, Intra-arterial
01

Overview

[Dpr3]ghrelin(1-20) is an experimental **ghrelin peptide analogue** derived from the N-terminal 20-amino-acid fragment of ghrelin, with substitution of **diaminopropionic acid at residue 3** to preserve the acylation handle required for receptor recognition while enabling chemical optimization. It has been studied in preclinical medicinal chemistry programs as a **growth hormone secretagogue receptor agonist scaffold** for improving ghrelin-like activity, receptor affinity, helicity, and proteolytic stability, including as a precursor framework for stapled ghrelin analogues. The available evidence indicates this is a research-stage peptide tool compound rather than a clinically developed therapeutic product, with no identified brand, company-sponsored development program, or marketed formulation.

Other names
Dpr3-ghrelin(1-20)ghrelin(1-20) analogue with Dpr at position 3
02

Targets

GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on [Dpr3]ghrelin(1-20).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [Dpr3]ghrelin(1-20).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call